Additional Data Published on the Beneficial Effect of EECP® Therapy in Patients with Abnormal Glucose Tolerance

October 24, 2012 (Westbury, New York) - VasoMedical, Inc. (“VasoMedical”) (OTCQB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced the publication of a study on the anti-inflammatory effects of Enhanced External Counterpulsation (EECP®) Therapy in patients with non-insulin dependent abnormal glucose tolerance (AGT).

The online publication of this original investigation, entitled Anti-inflammatory Effects of Enhanced External Counterpulsation in Subjects with Abnormal Glucose Tolerance and authored by JS Martin and R Braith at the Department of Applied Physiology and Kinesiology and the Division of Cardiovascular Medicine at the University of Florida in Gainesville, on October 11, 2012 in Applied Physiology, Nutrition and Metabolism, provided novel evidence that EECP® Therapy has a beneficial effect on circulating markers of systemic inflammation in subjects with AGT. This paper reaffirms the beneficial effects of EECP® Therapy not only in the management of glycemic control in AGT patients as reported in a previously published study by the same group, but also in reducing inflammatory markers such as high sensitivity C-reactive protein (hs-CRP) (by 27%) and tumor necrosis factor-α (TNF-α) (by 7%). The data were consistent with prior evidence published also by the same group on the decrease of circulating concentrations of pro-inflammatory markers in patients with coronary artery disease.

Further information on this newly published paper can be found by following the link:

In addition, this study provides evidence to support the concept that EECP® Therapy improves endothelial function thereby enhancing insulin utilization, as demonstrated by the significant correlation between changes from baseline in hs-CRP and homeostasis Model Assessment of insulin resistance, as well as between change from baseline in TNF-α and change from baseline in postprandial glucose 120 minutes after an oral glucose challenge. This is another published study by this group on EECP® Therapy on diabetes patients without coronary artery disease though their diabetes status put them in a high cardiovascular risk status.

“Recent understanding in the reduction of mortality and morbidity of type 2 diabetes mellitus is not only in the control of blood glucose levels but also cardiovascular related risk factors, especially inflammatory responses which promote progression of atherosclerosis,” stated Dr. John Hui, Chief Technology Officer of VasoMedical. “These pioneering works from University of Florida focus not only on the control of glycemic level in diabetes, but also on the prevention and management of cardiovascular risk factors. I believe their great contribution will eventually lead to expanded clinical applications of EECP® Therapy.”

Home | Back to News

©2017 Vaso Corporation